Europe surveillance initiative profiling the anti-staphylococcal activity of telavancin by specimen source from 2004 to 2005
Abstract number: 1733_322
Draghi D., Benton B., Jones M., Krause K., Thornsberry C., Sahm D.
Objectives: The increase and spread of methicillin (oxacillin)-resistant staphylococci present challenges for clinicians. Telavancin (TLV), a novel, rapidly bactericidal lipoglycopeptide, has recently completed two Phase 3 clinical trials for the treatment of complicated skin and skin structure infections. Ongoing trials are assessing TLV for the treatment of hospital-acquired pneumonia. Surveillance was initiated to establish a baseline for the activity of TLV against recent staphylococcal isolates, according to specimen source (SPEC).
Methods: Overall, 1721 Staphylococcus aureus (SA) and 226 coagulase-negative staphylococcus (CoNS) isolates were collected from Europe (33 hospital sites in 14 countries) during 20042005. Isolates were centrally tested by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) methodology (M7-A7) against TLV and comparators. Isolates were analysed in groups by SPEC, which included blood, skin structure, upper respiratory tract (SA only) and lower respiratory tract (SA only).
Results: The oxacillin-resistance (OX-R) rate for all SA was 30.5% and the OX-R rate for CoNS was 73.5%. The activity of TLV against the SA and CoNS isolates is shown in the Table. Based on MIC90 values, TLV (0.5 mg/L) was 16 times more potent than teicoplanin (TEI; 8 mg/L) against CoNS. Additionally, MIC ranges for TLV (0.062 mg/L) were lower compared with TEI (0.2532 mg/L).
Conclusion: TLV demonstrated potent activity against all SA and CoNS isolates, regardless of SPEC or resistance to oxacillin or TEI. This evaluation of TLV activity will provide a baseline for comparison of in vitro activity as clinical development and use progresses.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|